{"product_id":"biolegend-135223","title":"Biolegend, 135223, APC\/Cyanine7 anti-mouse CD279 (PD-1) Antibody, 25μg","description":"\u003cp\u003eCD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.\u003cbr\u003e\n25μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: PD-1 cDNA followed by PD-1-Ig fusion protein\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with APC\/Cyanine7 under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Zander R, et al. 2022. Elife. 11:. PubMed Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed Zander R, et al. 2022. Immunity. 55:475. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Xu W et al. 2019. Immunity. 50(4):1054-1068 . PubMed Ersching J et al. 2017. Immunity. 46(6):1045-1058 . PubMed Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed Snell LM, et al. 2018. Immunity. 49:678. PubMed Li J, et al. 2018. Immunity. 49:178. PubMed Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed Zhou J, et al. 2022. Int J Oncol. 61: . PubMed Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed Song X, et al. 2022. Transl Oncol. 15:101306. PubMed\u003cbr\u003e\nRRID: AB_2563522 (BioLegend Cat. No. 135223) AB_2563523 (BioLegend Cat. No. 135224)\u003cbr\u003e\nStructure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.\u003cbr\u003e\nDistribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.\u003cbr\u003e\nFunction: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.\u003cbr\u003e\nLigand\/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)\u003cbr\u003e\nCell Type: B cells, T cells\u003cbr\u003e\nBiology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules\u003cbr\u003e\nMolecular Family: CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nAntigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313\u003cbr\u003e\nGene ID: 18566\u003cbr\u003e\nUniProt: View information about CD279 on UniProt.org\u003cbr\u003e\nClone: 29F.1A12\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: PD-1, Programmed Death-1, PDCD1\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46866547835049,"sku":"135223","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-135223","provider":"Iright","version":"1.0","type":"link"}